These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Consider drug efficacy before first-in-human trials. Kimmelman J; Federico C Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789 [No Abstract] [Full Text] [Related]
4. [Preclinical research. Seal of approval translational medicine]. Hermann S; Pichler B; Kotzerke J Nuklearmedizin; 2013 Dec; 52(6):N53-4. PubMed ID: 24337015 [No Abstract] [Full Text] [Related]
5. Animal models: Mouse already being charted gene by gene. Brown S Nature; 2014 Apr; 508(7496):319. PubMed ID: 24740057 [No Abstract] [Full Text] [Related]
6. Reverse translation of failed treatments can help improving the validity of preclinical animal models. 't Hart BA Eur J Pharmacol; 2015 Jul; 759():14-8. PubMed ID: 25823810 [TBL] [Abstract][Full Text] [Related]
7. Increase of disease duration of amyotrophic lateral sclerosis in a mouse model by transgenic small interfering RNA. Yokota T; Sasaguri H; Saito Y; Yamada H; Unno T; Yamamoto Y; Kubodera T; Anzai M; Mitani T; Mizusawa H Arch Neurol; 2007 Jan; 64(1):145-6. PubMed ID: 17210827 [No Abstract] [Full Text] [Related]
8. Drug development: Raise standards for preclinical cancer research. Begley CG; Ellis LM Nature; 2012 Mar; 483(7391):531-3. PubMed ID: 22460880 [No Abstract] [Full Text] [Related]
9. Selecting promising ALS therapies in clinical trials. Glass JD; Benatar M; Polak M Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765 [No Abstract] [Full Text] [Related]
10. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Benatar M Neurobiol Dis; 2007 Apr; 26(1):1-13. PubMed ID: 17300945 [TBL] [Abstract][Full Text] [Related]
11. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis? Butsch PO; Cudkowicz ME Exp Neurol; 2007 Jul; 206(1):11-5. PubMed ID: 17498699 [No Abstract] [Full Text] [Related]
12. Has gene therapy for ALS arrived? Miller TM; Cleveland DW Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369 [No Abstract] [Full Text] [Related]
17. The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS. Kong Q; Carothers S; Chang Y; Glenn Lin CL CNS Neurosci Ther; 2012 Sep; 18(9):791-3. PubMed ID: 22712693 [No Abstract] [Full Text] [Related]
18. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555 [TBL] [Abstract][Full Text] [Related]
19. Preclinical studies of human disease: time to take methodological quality seriously. van der Worp HB; Macleod MR J Mol Cell Cardiol; 2011 Oct; 51(4):449-50. PubMed ID: 21549125 [No Abstract] [Full Text] [Related]
20. [Research in amyotrophic lateral sclerosis: what is new in 2009?]. Pradat PF; Attarian S; Camdessanché JP; Carluer L; Cintas P; Corcia P; Echaniz-Laguna A; Gonzalez-Bermejo J; Guy N; Nicolas G; Perez T; Soriani MH; Vandenberghe N; Verschueren A; Rev Neurol (Paris); 2010; 166(8-9):683-98. PubMed ID: 20472259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]